Acorda Therapeutics, Inc. (ACOR): Price and Financial Metrics
ACOR Price/Volume Stats
| Current price | $0.66 | 52-week high | $24.20 |
| Prev. close | $0.88 | 52-week low | $0.61 |
| Day low | $0.61 | Volume | 416,900 |
| Day high | $0.85 | Avg. volume | 119,299 |
| 50-day MA | $11.81 | Dividend yield | N/A |
| 200-day MA | $13.10 | Market Cap | 820.96K |
ACOR Stock Price Chart Interactive Chart >
Acorda Therapeutics, Inc. (ACOR) Company Bio
Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The company was founded in 1995 and is based in Ardsley, New York.
Latest ACOR News From Around the Web
Below are the latest news stories about ACORDA THERAPEUTICS INC that investors may wish to consider to help them evaluate ACOR as an investment opportunity.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call TranscriptAcorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Welcome to Acorda Therapeutics Third Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company’s request. […] |
Acorda Therapeutics Reports Third Quarter 2023 Financial ResultsPEARL RIVER, N.Y., November 13, 2023--Acorda Therapeutics Reports Third Quarter 2023 Financial Results |
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023PEARL RIVER, N.Y., November 06, 2023--Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023 |
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®PEARL RIVER, N.Y., November 06, 2023--Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA® |
Acorda Therapeutics (ACOR): A Comprehensive Analysis of Its Market ValueUnveiling the Intrinsic Value of Acorda Therapeutics |
ACOR Price Returns
| 1-mo | -94.55% |
| 3-mo | -96.17% |
| 6-mo | -93.36% |
| 1-year | -92.98% |
| 3-year | -99.30% |
| 5-year | -99.95% |
| YTD | -95.63% |
| 2023 | -1.59% |
| 2022 | -67.92% |
| 2021 | -42.28% |
| 2020 | -66.17% |
| 2019 | -86.91% |
Continue Researching ACOR
Here are a few links from around the web to help you further your research on Acorda Therapeutics Inc's stock as an investment opportunity:Acorda Therapeutics Inc (ACOR) Stock Price | Nasdaq
Acorda Therapeutics Inc (ACOR) Stock Quote, History and News - Yahoo Finance
Acorda Therapeutics Inc (ACOR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...